A diverse array of HER2‐directed agents—including monoclonal antibodies (mAbs), tyrosine kinase inhibitors (TKIs) and ADCs—have been developed, significantly improving survival outcomes for patients with HER2+ BC in both early and advanced stages [72, 73, 74, 75, 76]. Here, ERBB2 is linked to breast cancer.